We have to send the verification link to your mailbox, please check and verify
Did not receive verification mail? Please confirm whether the mailbox is correct or not Re send mail
Determine

4th China Pharma IP Summit 2019,Oct 23-25,Shanghai China

De

2019-07-08 09:57:13

英2.jpg


4th China Pharma IP Summit 2019 (CPIPS2019) organized by Shanghai YIP Events, Supported by Pharma IP Right Research Committee of Chinese Pharmaceutical Association , which will be held on 23rd -25th , Oct this year at Primus Hotel Shanghai Hongqiao China.


As a dedicated event to pharmaceutical intellectual property, In the past three years CPIPS has gathered more than 1000 attendees from relevant government departments(CNIPA/EPO/JPO/USPTO), industry associations, global and china local pharma/biotech companies, law firms, IP agencies, IP solution providers and so on. CPIPS topics covered the IP protection and hot issues in all over the world, include mainly China, Europe, US, Japan, South Korea and India. CPIPS is currently the best and largest Pharma IP focused event in China, this year CPIPS will attract more than 500 pharma IP peers from all over the world.


Hot Topics that will be Presented and Discussed :

  • Drug Regulatory Updates and Outlook in China

  • Examination of Invalidation Cases and Practice of Pharma Compound Patent Examination

  • Patent Linkage, Patent Term Restoration in China

  • Identification and Persuasion Strategy of Technical Facts in Pharma Patent Cases

  • Data Supplementation for Chemical and Biotech Patents

  • Trade (Technical) Secret Infringement and Protection of the Pharma Industry

  • Patent Protection of Biological Sequences

  • Evaluation of Inventive Step of Pharmaceutical Compound Inventions

  • Latest Developments of IPR and Recent Patent Invalidation Cases

  • The Strategy of ANDA Filers to Challenge Patents Under a PIV Certification and Recent ANDA Litigation Cases Study

  • Identifying the Loss of Exclusivity (LoE) of a U.S. Pharmaceutical Patent Portfolio

  • U.S. Biosimilar Patent Litigation: Strategies and Trends

  • Oncology IP Portfolio Development and Strategy and Implications Under the Current US-China Politic/Economic Environment

  • UPC and UPS - Why does it Make Sense for Europe and What Could be the Impact of Brexit?

  • Recent European Regulatory Developments on Supplementary Protection Certificates (SPCs)

  • How to Build a Successful Licensing Program and Other Strategies for IP Monetization

  • Panel Discussion: Global Patent Issues of Therapeutic Antibodies

  • Biosimilars in US,EU and China: Where Are We Now and Where Are We Going?

  • Patent System and Practice of Medical Fields and Patent Term Extension in Japan

  • IP Management & Practices Adopted by Generic Drug Manufacturers from India

  • Patent System for Pharmaceutical Invention

  • Life Sciences: IP and Regulatory Environment in Brazil and selected Latin American Jurisdictions

  • Expanding International Business :Strategy to Grow and Optimize Generic Portfolio in New Geographies (ROW countries)

  • Patenting Situation of TCM and Studies from Invalidation Cases

  • Rethinking of Patent Creative Evaluation for Traditional Chinese Medicine

  • Protect the Technologies from Traditional Chinese Medicine: Challenges and Opportunities

  • IP Challenges and Strategy for Traditional Chinese Medicine ‘Going Out’


Confirmed Speakers as of June 30th :

  • Qingkui Zhang,Honorary Director,Pharma IP Right Research Committee

  • Qiujuan Ma,Director of Pharmaceutical Division,Patent Examination Cooperation (Beijing) Center of The Patent Office,CNIPA New

  • Jiangming Wu,Deputy Director,Patent Examination Cooperation Jiangsu Center of The Patent Office, CNIPA New

  • Peter Storm, Senior Patent Attorney, AstraZeneca New

  • Lareina Chen,IP Manager,Shanghai Junshi Biosciences New

  • Songyan Rui,Judge, Beijing Intellectual Property Court New

  • Bo Xu, Judge, Beijing Intellectual Property Court New

  • Hou Yao, Researcher, Reexamination and Invalidation Department of the Patent Office, CNIPA

  • Xiangjun Li,Vice President,SHIJIAZHUANG YILING PHARMACEUTICAL New

  • Yongshun Cheng,Director,Beijing Intellectual Property Institute

  • Yang Xu, Patent Attorney, BeiGene, Ltd.

  • Wenjun Geng,IP Director,CHIA TAI TIANQING PHARMACEUTICAL GROUP

  • Lifang Sun, IP Vice President,Luye Pharma Group New

  • Nick Qinghui Liu,Partner,Anjie Law Firm

  • Xiaoting Song,Professor, Tongji University New

  • Caihui Li,Senior IP Director, 3SBio Group New

  • Bo Xu, Judge, Beijing Intellectual Property Court New

  • Feng Xu, IP Director for China and Asia, AstraZeneca

  • Wu Li,Partner, Anjie Law Firm

  • Wenping Chen, Partner, King & Wood Mallesons New

  • Tina Tai, Partner,King & Wood Mallesons New

  • Michael Wise, Partner, Perkins Coie LLP New

  • Shashank Upadhye, Partner, Upadhye Cwik LLP

  • Carl A. Morales, Partner, Dechert LLP New

  • Gang Wang, Associate, Dechert LLP New

  • Xiarui Dou, IP Director,Yabao Pharmaceutical Group New

  • Yite John Lu, Partner, Irell & Manella LLP New

  • Andy Zhang,Senior Corporate Counsel, Intellectual Property, Sunovion Pharmaceutical New

  • Teresa Lavoie,Principal, Fish & Richardson P.C. New

  • Dr. Joerg Thomaier, Head of IP, Bayer Group New

  • Wanli Tang, Associate, Jones Day

  • Tony Chen,Partner,Jones Day

  • Bharati Nadkarni, Vice President Portfolio Planning and IP litigation,Sun Pharmaceutical New

  • Yehudah Livneh, Former General Patent Counsel and VP Corporate IP , Teva Pharmaceuticals New

  • Chris Goddard, Partner, Dehns Patent and Trade Mark Attorneys New

  • Toru Matsuoka, Deputy Director, Examination Standards Office,JPO New

  • Poonam Raghuvanshi, Vice President & Head of IP, Dr. Reddy's Laboratories Ltd. New

  • Ilseok Alban Kang, Patent Attorney, FirstLaw P. C. New

  • Gustavo Morais, Partner,IP Agent, Dannemann Siemsen New

  • Ana Carneiro, Partner, IP Agent, Dannemann Siemsen New

  • Yongfeng Zheng,Legal Director and Vice Dean of Research Institute, Tasly Holding Group New

  • Peter L. Dolan,Strategy and Business Development Senior Director,Sanofi

  • Dr. Christof Bull,Associate General Patent Counsel,UCB Biopharma

  • Daisy Wu, IP Director,Shanghai Henlius Biotech,Inc. New

  • Mahendra B. Thakre,Senior General Manager, Global IP, Mylan Laboratories Limited


Past CPIPS Information please visit below:

3rd China Pharma Intellectual Property Summit 2018

2nd China Pharma Intellectual Property Summit 2017

China Pharma Intellectual Property Summit 2016


Contact Organizer below to register or get the latest agenda for this year or visit conference website at www.pharmaip.cn


Johnson Li

Conference Manager

Tel: 86 21 6142 1083

Mobile: 86 189 1779 8290 (Wechat)

Email: johnson.li@yipevents.com

Web:www.pharmaip.cn


Source:iprdaily.com

Editor:De

    I also said the two sentence
    Also you can enter 140words
    I want to comment.
    Reply
    Also you can enter 70 words